GeoVax Labs receives Nasdaq notice for non-compliance with minimum bid price

GeoVax Labs, Inc. (NASDAQ:GOVX), currently trading at $0.72 and showing significant volatility according to InvestingPro data, announced Friday that it received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market. The notice states that for the previous 30 consecutive business days, the closing bid price for the company’s common stock was below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market, as stipulated by Nasdaq Listing Rule 5550(a)(2).

According to a statement in the company’s SEC filing, GeoVax has been granted an initial compliance period of 180 calendar days, until January 27, 2026, to meet the minimum bid price requirement. If at any time before this compliance date the closing bid price of the company’s common stock reaches at least $1.00 for a minimum of 10 consecutive business days, Nasdaq staff will provide written confirmation that the company has regained compliance.

If the company does not regain compliance by the deadline, it may be eligible for an additional 180-day period, subject to meeting all other listing standards except for the bid price requirement. To qualify for this extension, GeoVax would need to notify Nasdaq of its intention to cure the deficiency, which could include implementing a reverse stock split if necessary.

Should GeoVax fail to regain compliance and not qualify for an additional compliance period, Nasdaq staff will notify the company that its common stock is subject to delisting. At that point, GeoVax would have the opportunity to appeal the decision to a Nasdaq Hearing Panel.

The company stated that the notification has no immediate effect on the listing of its common stock, which will continue to trade on the Nasdaq Capital Market under the symbol GOVX. GeoVax indicated it will monitor the closing bid price and may consider available options to regain compliance. With a current market capitalization of $18.3 million and an overall WEAK financial health score according to InvestingPro, investors can access detailed analysis and 13 additional ProTips about GeoVax through InvestingPro’s comprehensive research reports.

This information is based on a press release statement included in the company’s recent SEC filing.

In other recent news, GeoVax Labs Inc. reported a significant increase in revenue during its Q2 2025 earnings call. The company announced that its six-month revenues surged to $2.5 million, a notable rise from $301,000 in the same period last year. This substantial growth underscores GeoVax Labs’ continued efforts in vaccine and cancer therapy advancements. Despite the impressive revenue figures, the company’s stock experienced a decline during regular trading hours. However, it showed a slight recovery in aftermarket trading. The financial landscape remains challenging for GeoVax Labs as it navigates its strategic focus areas. These recent developments highlight the company’s ongoing commitment to innovation in its field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.